Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain

Tomoko Kurata, Hiromi Kawai, Kazunori Miyazaki, Miki Kozuki, Nobutoshi Morimoto, Yasuyuki Ohta, Yoshio Ikeda, Koji Abe

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Structural and functional abnormalities in the neurovascular unit (NVU) have been recently observed in Alzheimer's disease (AD). Statins, which are used clinically for reducing cholesterol levels, can also exert beneficial vascular actions, improve behavioral memory and reduce senile plaque (SP). Thus, we examined cognitive function, the serum level of lipids, senile plaque (SP), and the protective effects of statins on NVU disturbances in a mouse AD model. Amyloid precursor protein (APP) transgenic (Tg) mice were used as a model of AD. Atorvastatin (30 mg/kg/day, p.o.) or pitavastatin (3 mg/kg/day, p.o.) were administered from 5 to 20 months of age. These 2 statins improved behavioral memory and reduced the numbers of SP at 15 and 20 M without affecting serum lipid levels. There was a reduction in immunopositive staining for N-acetyl glucosamine oligomer (NAGO) in the endothelium and in collagen IV in the APP vehicle (APP/Ve) group, with collagen IV staining most weakest near SP. There was also an increase in intensity and numbers of glial fibrillary acidic protein (GFAP) positive astrocytes, particularly around the SP, where MMP-9 was more strongly labeled. Double immunofluorescent analysis showed that astrocytic endfeet had detached from the capillary endothelium in the APP/Ve group. Overall, these data suggest that statins may have therapeutic potential for AD by protecting NVU.

Original languageEnglish
Pages (from-to)59-63
Number of pages5
JournalJournal of the Neurological Sciences
Volume322
Issue number1-2
DOIs
Publication statusPublished - Nov 15 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Amyloid Plaques
Alzheimer Disease
Amyloid beta-Protein Precursor
Brain
Collagen
Staining and Labeling
Lipids
Therapeutics
Glucosamine
Glial Fibrillary Acidic Protein
Vascular Endothelium
Serum
Matrix Metalloproteinases
Astrocytes
Cognition
Transgenic Mice
Endothelium
Blood Vessels
Cholesterol

Keywords

  • Alzheimer's disease
  • Neurovascular unit
  • Senile plaque
  • Statin
  • Transgenic mouse

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. / Kurata, Tomoko; Kawai, Hiromi; Miyazaki, Kazunori; Kozuki, Miki; Morimoto, Nobutoshi; Ohta, Yasuyuki; Ikeda, Yoshio; Abe, Koji.

In: Journal of the Neurological Sciences, Vol. 322, No. 1-2, 15.11.2012, p. 59-63.

Research output: Contribution to journalArticle

Kurata, Tomoko ; Kawai, Hiromi ; Miyazaki, Kazunori ; Kozuki, Miki ; Morimoto, Nobutoshi ; Ohta, Yasuyuki ; Ikeda, Yoshio ; Abe, Koji. / Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. In: Journal of the Neurological Sciences. 2012 ; Vol. 322, No. 1-2. pp. 59-63.
@article{11b82a2f94d84b148c780f132a3e1126,
title = "Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain",
abstract = "Structural and functional abnormalities in the neurovascular unit (NVU) have been recently observed in Alzheimer's disease (AD). Statins, which are used clinically for reducing cholesterol levels, can also exert beneficial vascular actions, improve behavioral memory and reduce senile plaque (SP). Thus, we examined cognitive function, the serum level of lipids, senile plaque (SP), and the protective effects of statins on NVU disturbances in a mouse AD model. Amyloid precursor protein (APP) transgenic (Tg) mice were used as a model of AD. Atorvastatin (30 mg/kg/day, p.o.) or pitavastatin (3 mg/kg/day, p.o.) were administered from 5 to 20 months of age. These 2 statins improved behavioral memory and reduced the numbers of SP at 15 and 20 M without affecting serum lipid levels. There was a reduction in immunopositive staining for N-acetyl glucosamine oligomer (NAGO) in the endothelium and in collagen IV in the APP vehicle (APP/Ve) group, with collagen IV staining most weakest near SP. There was also an increase in intensity and numbers of glial fibrillary acidic protein (GFAP) positive astrocytes, particularly around the SP, where MMP-9 was more strongly labeled. Double immunofluorescent analysis showed that astrocytic endfeet had detached from the capillary endothelium in the APP/Ve group. Overall, these data suggest that statins may have therapeutic potential for AD by protecting NVU.",
keywords = "Alzheimer's disease, Neurovascular unit, Senile plaque, Statin, Transgenic mouse",
author = "Tomoko Kurata and Hiromi Kawai and Kazunori Miyazaki and Miki Kozuki and Nobutoshi Morimoto and Yasuyuki Ohta and Yoshio Ikeda and Koji Abe",
year = "2012",
month = "11",
day = "15",
doi = "10.1016/j.jns.2012.06.011",
language = "English",
volume = "322",
pages = "59--63",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain

AU - Kurata, Tomoko

AU - Kawai, Hiromi

AU - Miyazaki, Kazunori

AU - Kozuki, Miki

AU - Morimoto, Nobutoshi

AU - Ohta, Yasuyuki

AU - Ikeda, Yoshio

AU - Abe, Koji

PY - 2012/11/15

Y1 - 2012/11/15

N2 - Structural and functional abnormalities in the neurovascular unit (NVU) have been recently observed in Alzheimer's disease (AD). Statins, which are used clinically for reducing cholesterol levels, can also exert beneficial vascular actions, improve behavioral memory and reduce senile plaque (SP). Thus, we examined cognitive function, the serum level of lipids, senile plaque (SP), and the protective effects of statins on NVU disturbances in a mouse AD model. Amyloid precursor protein (APP) transgenic (Tg) mice were used as a model of AD. Atorvastatin (30 mg/kg/day, p.o.) or pitavastatin (3 mg/kg/day, p.o.) were administered from 5 to 20 months of age. These 2 statins improved behavioral memory and reduced the numbers of SP at 15 and 20 M without affecting serum lipid levels. There was a reduction in immunopositive staining for N-acetyl glucosamine oligomer (NAGO) in the endothelium and in collagen IV in the APP vehicle (APP/Ve) group, with collagen IV staining most weakest near SP. There was also an increase in intensity and numbers of glial fibrillary acidic protein (GFAP) positive astrocytes, particularly around the SP, where MMP-9 was more strongly labeled. Double immunofluorescent analysis showed that astrocytic endfeet had detached from the capillary endothelium in the APP/Ve group. Overall, these data suggest that statins may have therapeutic potential for AD by protecting NVU.

AB - Structural and functional abnormalities in the neurovascular unit (NVU) have been recently observed in Alzheimer's disease (AD). Statins, which are used clinically for reducing cholesterol levels, can also exert beneficial vascular actions, improve behavioral memory and reduce senile plaque (SP). Thus, we examined cognitive function, the serum level of lipids, senile plaque (SP), and the protective effects of statins on NVU disturbances in a mouse AD model. Amyloid precursor protein (APP) transgenic (Tg) mice were used as a model of AD. Atorvastatin (30 mg/kg/day, p.o.) or pitavastatin (3 mg/kg/day, p.o.) were administered from 5 to 20 months of age. These 2 statins improved behavioral memory and reduced the numbers of SP at 15 and 20 M without affecting serum lipid levels. There was a reduction in immunopositive staining for N-acetyl glucosamine oligomer (NAGO) in the endothelium and in collagen IV in the APP vehicle (APP/Ve) group, with collagen IV staining most weakest near SP. There was also an increase in intensity and numbers of glial fibrillary acidic protein (GFAP) positive astrocytes, particularly around the SP, where MMP-9 was more strongly labeled. Double immunofluorescent analysis showed that astrocytic endfeet had detached from the capillary endothelium in the APP/Ve group. Overall, these data suggest that statins may have therapeutic potential for AD by protecting NVU.

KW - Alzheimer's disease

KW - Neurovascular unit

KW - Senile plaque

KW - Statin

KW - Transgenic mouse

UR - http://www.scopus.com/inward/record.url?scp=84867579493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867579493&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2012.06.011

DO - 10.1016/j.jns.2012.06.011

M3 - Article

C2 - 22795384

AN - SCOPUS:84867579493

VL - 322

SP - 59

EP - 63

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -